How GLP-1RA Reduce Reward-Driven Feeding: Hypothalamic and Mesolimbic Circuits
Abstract
Glucagon-like peptide-1 (GLP-1) receptor agonists reduce reward-driven feeding by acting on hypothalamic and mesolimbic circuits, particularly through anticipatory satiation and modulation of reward processing. Converging evidence shows that these drugs reduce food intake, enhance satiation, and decrease the motivational value of palatable food. Hypothalamic findings suggest that GLP-1 signaling promotes satiety by engaging dorsomedial hypothalamic pathways and suppressing downstream hunger-related signaling. This promotes Agouti-related Protein (AgRP) inhibition in the arcuate nucleus and enhances physiological satiation signals, overall increasing satiation and decreasing hunger drive. Complementary mesolimbic evidence indicates that GLP-1 receptor activation influences food motivation and reward processing through pathways linking the nucleus of solitary tract and lateral dorsal tegmental nucleus to downstream reward circuitry including the ventral tegmental area to the ventral striatum. This effectively results in reduced motivated feeding and a decreased willingness to work for food. Although overall literature supports a dual homeostatic and hedonic mechanism, direct mechanistic evidence in humans remains limited. Additionally, limited accessibility for lower-income populations reduces the real-world applicability of these findings. Based on the evidence, the recommendation is for adults with obesity, future 12-week randomized trials should test whether GLP-1 receptor agonists reduce reward-driven feeding by measuring anticipatory satiation, ad libitum food intake, and motivation for palatable food.